(1) Background: Recent publications foster stereotactic body radiotherapy (SBRT) in patients with adrenal oligometastases or oligoprogression. However, local control (LC) after non-adaptive SBRT shows the potential for improvement. Online adaptive MR-guided SBRT (MRgSBRT) improves tumor coverage and organ-at-risk (OAR) sparing. Long-term results of adaptive MRgSBRT are still sparse. (2) Methods: Adaptive MRgSBRT was performed on a 0.35 T MR-Linac. LC, overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and toxicity were assessed. (3) Results: 35 patients with 40 adrenal metastases were analyzed. The median gross tumor volume was 30.6 cc. The most common regimen was 10 fractions at 5 Gy. The median biologically effective dose (BED10) was 75.0 Gy. Plan adaptation was performed in 98% of all fractions. The median follow-up was 7.9 months. One local failure occurred after 16.6 months, resulting in estimated LC rates of 100% at one year and 90% at two years. ORR was 67.5%. The median OS was 22.4 months, and the median PFS was 5.1 months. No toxicity > CTCAE grade 2 occurred. (4) Conclusions: LC and ORR after adrenal adaptive MRgSBRT were excellent, even in a cohort with comparably large metastases. A BED10 of 75 Gy seems sufficient for improved LC in comparison to non-adaptive SBRT.
To evaluate the efficacy and safety of carbon ion radiotherapy (CIRT) in patients with non-metastatic, inoperable pancreatic cancer in a prospective phase 2 setting. In this single-center investigator-initiated phase 2 trial, 25 patients with locally advanced or locally recurrent pancreatic cancer were included. CIRT was performed using an intensity-controlled rasterscanning system for beam application [total dose: 48 Gy (RBE), 12 fractions]. Concurrent chemotherapy with Gemcitabine 300 mg/m2 was administered weekly. The primary endpoint was the 1-year OS rate, defined as time from study inclusion. 1y- and 2y-OS and -PFS were calculated using the Kaplan-Meier method, 95 % confidence intervals are shown. Toxicity was evaluated using CTCAEv5.0. Twenty-three patients were included in the final analysis. After the completed 12-month follow-up of the last patient, the 1- and 2-year OS rates were 78 % [CI 63 %; 97 %] and 59 % [CI 41 %; 84 %]. The median OS was 26.5 months. The 1- and 2-year PFS rates were 26 % [CI 13 %; 52 %] and 10 % [CI 3 %; 37 %] with a median PFS of 8.1 months. Study treatment was well tolerated with three treatment-related CTCAE grade 3 toxicities, including one case of abdominal pain, one upper gastrointestinal hemorrhage and one ureteric stricture. No treatment-related CTCAE grade 4-5 toxicities were observed. Chemoradiation with carbon ions demonstrated encouraging overall survival and acceptable toxicity in non-metastatic pancreatic cancer patients. A subsequent randomized Phase 3 trial should investigate OS superiority of CIRT compared to conventional chemoradiotherapy or chemotherapy.